Formulation and Characterization of Simvastatin-Loaded Nanosponges: An Innovative Technique for Colon-Targeted Drug Delivery

Vanapalli Swapna, Rajeswari Saripilli, Kudumala Sravya, Dinesh Kumar Sharma
{"title":"Formulation and Characterization of Simvastatin-Loaded Nanosponges: An Innovative Technique for Colon-Targeted Drug Delivery","authors":"Vanapalli Swapna, Rajeswari Saripilli, Kudumala Sravya, Dinesh Kumar Sharma","doi":"10.2174/0124681873297155240220062817","DOIUrl":null,"url":null,"abstract":"\n\nTo enhance the solubility of simvastatin by improving the surface area of the drug particle by preparing nanosponges that are enclosed in a tablet and capsule oral solid dosage forms, which in turn helps maintain the drug's stability.\n\n\n\nThe present investigation aimed to develop a simvastatin nanosponge containing Eu-dragit as a polymer with different ratios of drug-to-polymer concentration to increase its solubility and further improve the oral bioavailability by using nanosponges’ formulation technique.\n\n\n\nThe emulsion solvent diffusion method was used to prepare simvastatin nanosponges by using Eudragit S 100, Eudragit L 100, and a combination of both in different drug-to-polymer ratios, i.e., 1:0.5, 1:1, 1:1.5, and 1:2. To characterize the conductivity, molecular changes, and size of the prepared nanosponges, a variety of evaluation parameters, including the compressibil-ity index, Hausner's ratio, angle of repose, microscopy, production yield, entrapment efficiency, drug content, in vitro drug release studies, DSC, XRD, FTIR, and SEM were evaluated. Opti-mized formulation was used to prepare colon-targeted tablets and capsules by taking nanosponges equivalent to 20 mg of simvastatin.\n\n\n\nThe percentage yield, drug content, and entrapment efficiency of the final formulation were observed at 81 ± 0.26%, 92.4%, and 97 ± 0.56%, respectively. The in vitro drug release of the optimized formulations was 91.42 % at 12 hrs. The drug release followed the Peppas model with a super case II transport mechanism.\n\n\n\nThe use of the nanosponge delivery system increased the solubility of simvastatin seven times, which in turn increased the drug's bioavailability.\n","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":"136 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Nanomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0124681873297155240220062817","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

To enhance the solubility of simvastatin by improving the surface area of the drug particle by preparing nanosponges that are enclosed in a tablet and capsule oral solid dosage forms, which in turn helps maintain the drug's stability. The present investigation aimed to develop a simvastatin nanosponge containing Eu-dragit as a polymer with different ratios of drug-to-polymer concentration to increase its solubility and further improve the oral bioavailability by using nanosponges’ formulation technique. The emulsion solvent diffusion method was used to prepare simvastatin nanosponges by using Eudragit S 100, Eudragit L 100, and a combination of both in different drug-to-polymer ratios, i.e., 1:0.5, 1:1, 1:1.5, and 1:2. To characterize the conductivity, molecular changes, and size of the prepared nanosponges, a variety of evaluation parameters, including the compressibil-ity index, Hausner's ratio, angle of repose, microscopy, production yield, entrapment efficiency, drug content, in vitro drug release studies, DSC, XRD, FTIR, and SEM were evaluated. Opti-mized formulation was used to prepare colon-targeted tablets and capsules by taking nanosponges equivalent to 20 mg of simvastatin. The percentage yield, drug content, and entrapment efficiency of the final formulation were observed at 81 ± 0.26%, 92.4%, and 97 ± 0.56%, respectively. The in vitro drug release of the optimized formulations was 91.42 % at 12 hrs. The drug release followed the Peppas model with a super case II transport mechanism. The use of the nanosponge delivery system increased the solubility of simvastatin seven times, which in turn increased the drug's bioavailability.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
辛伐他汀负载纳米海绵的制备与表征:结肠靶向给药的创新技术
通过制备纳米海绵来提高辛伐他汀的溶解度,从而提高药物颗粒的表面积,并将其封装在片剂和胶囊口服固体制剂中,这反过来又有助于保持药物的稳定性。本研究旨在开发一种含有 Eu-dragit 作为聚合物的辛伐他汀纳米海绵,采用不同的药物与聚合物浓度比,以增加其溶解度,并利用纳米海绵制剂技术进一步提高其口服生物利用度、1:0.5、1:1、1:1.5 和 1:2。为了表征制备的纳米海绵的导电性、分子变化和尺寸,对各种评价参数进行了评估,包括压缩性指数、豪斯纳比率、静止角、显微镜、产量、夹持效率、药物含量、体外药物释放研究、DSC、XRD、傅立叶变换红外光谱和扫描电镜。取相当于 20 毫克辛伐他汀的纳米海绵制备结肠靶向片剂和胶囊,观察到最终制剂的得率百分比、药物含量和夹持效率分别为 81 ± 0.26%、92.4% 和 97 ± 0.56%。12 小时后,优化配方的体外药物释放率为 91.42%。纳米海绵给药系统将辛伐他汀的溶解度提高了七倍,从而提高了药物的生物利用度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Nanomedicine
Current Nanomedicine Medicine-Medicine (miscellaneous)
CiteScore
2.00
自引率
0.00%
发文量
15
期刊最新文献
Contemporary Nanoemulsion Research: Extensive Examination of Self-Nanoemulsifying Drug Delivery Systems Nanomedicine in Alzheimer’s Therapy: Enhancing Drug Delivery Strategies Nanosuspension as a Novel Nanovehicle for Drug Delivery: A Recent Update on Patents and Therapeutic Applications Nanotechnological Carriers in the Treatment of Cancer: A Review Nanocrystals in Drug Delivery: A Cutting-Edge Approach for Enhanced Therapeutic Values
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1